Trilostane

DB01108ApprovedVet approvedWithdrawnSmall molecule

Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.

Mechanism: Trilostane produces suppression of the adrenal cortex by inhibiting enzymatic conversion of steroids by 3-beta-hydroxysteroid dehydrogenase/delta 5,4 ketosteroid isomerase, thus blocking synthesis of adrenal steroids.
Curator reviewed
Primary indication: Used in the treatment of Cushing's syndrome.Curator reviewed
Formula / weight: C₂₀H₂₇NO₃ · 329.4333 g/mol (avg)
Code names: WIN-24540

Resolves to

Compound

UNIIL0FPV48Q5RCAS13647-35-3ChEMBLCHEMBL1200907ChEBI32260PubChem656583KEGGD01180

Clinical / RWD

RxNorm38668ATCH02CA01PharmGKBPA164748507

Structure

InChIKeyKVJXBPDAXMEYOA-CXANFOAXSA-NSMILES[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]23O[C@@H]2C(O)=C(C[C@]13C)C#N

Targets

P14060HSD3B1P26439HSD3B2P03372ESR1Q92731ESR2

What you can answer from here — as of September 12, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,050Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 23 drug categories

22+ReferencesStructured and connected to the statements they support

Which drugs share a target with Trilostane, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In